BRIEF-Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1

Reuters
20 Feb
BRIEF-Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase Of Glp-1

Feb 20 (Reuters) - Immunic Inc IMUX.O:

  • IMMUNIC'S ORAL IMU-856 DEMONSTRATED DOSE-DEPENDENT INCREASE OF GLP-1 IN CELIAC DISEASE PATIENTS AND CORRESPONDING EFFECTS IN PRECLINICAL TESTING

  • IMMUNIC INC: DOSE-DEPENDENT REDUCTION OF BODY WEIGHT GAIN AND FOOD CONSUMPTION OBSERVED IN PRECLINICAL STUDY

  • IMMUNIC: DOSE-DEPENDENT INCREASE OF ENDOGENOUS GLP-1 LEVELS OBSERVED IN POST HOC ANALYSIS OF PATIENTS FROM PHASE 1B CLINICAL TRIAL IN CELIAC DISEASE

Source text: ID:nPn12yQH3a

Further company coverage: IMUX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10